

Isopto[®] Atropine (atropine sulfate) – New Drug Approval

- On December 1, 2016, the <u>FDA approved</u> Alcon's <u>Isopto Atropine (atropine sulfate)</u> 1% ophthalmic solution, indicated for mydriasis, cycloplegia, and penalization of the healthy eye in the treatment of amblyopia.
 - Previously, Isopto Atropine was available as an unapproved drug. Alcon stopped distribution of the product.
- Isopto Atropine is a muscarinic antagonist. It causes dilation of the pupil and paralysis of the ciliary muscle which controls accommodation.
- Atropine sulfate is also available as a 1% ophthalmic solution by Akorn.
- The efficacy of Isopto Atropine has been demonstrated in adults and children for mydriasis and/or cycloplegia.
 - The maximum effect for mydriasis is achieved in about 30 − 40 minutes after administration, with recovery after approximately 7 − 10 days.
 - The maximum effect for cycloplegia is achieved within 60 180 minutes after administration, with recovery after approximately 7 – 12 days.
- Warnings and precautions of Isopto Atropine include photophobia and blurred vision, elevation of blood pressure, and increased adverse drug reaction susceptibility with certain central nervous system conditions.
- The most common adverse events with Isopto Atropine use were eye pain and stinging on administration, blurred vision, photophobia, superficial keratitis, decreased lacrimation, drowsiness, increased heart rate and blood pressure.
- The recommended dose of Isopto Atropine for individuals from ≥ 3 months of age is 1 drop topically to the cul-de-sac of the conjunctiva, 40 minutes prior to the intended maximal dilation time.
 - In individuals > 3 years of age, doses may be repeated up to twice daily as needed.
- Alcon immediately launched Isopto Atropine. Isopto Atropine is available as a 1% ophthalmic solution in 8 mL and 15 mL bottles.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.